A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Recruiting

Phase 1

Phase 2

E7386 & LenvatinibA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Sponsor:

Eisai Inc.

Code:

NCT04008797

Conditions

Neoplasms

Carcinoma, Hepatocellular

Liver Neoplasms

Colorectal Neoplasms

Endometrial Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

E7386

Lenvatinib

Doxorubicin

Paclitaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-03. This information was provided to ClinicalTrials.gov by Eisai Inc. on 2025-10-20.